Dozens of people sue GLP-1 drug companies over alleged vision loss
Summary
Dozens of people in the US have sued companies that make GLP-1 weight-loss drugs, like Ozempic and Mounjaro, claiming the drugs caused a rare eye condition that can lead to permanent vision loss. The drug makers deny the claims and say they are reviewing health data, while research shows mixed results on the connection between the drugs and the eye condition.Key Facts
- Dozens of lawsuits claim GLP-1 drugs caused nonarteritic anterior ischemic optic neuropathy (NAION), a rare eye condition that reduces blood flow to the optic nerve and can cause permanent vision loss.
- GLP-1 drugs, including Ozempic, Mounjaro, and Wegovy, are widely used for weight loss and diabetes treatment in the US.
- The lawsuits have been filed mainly against Novo Nordisk, a major manufacturer, in New Jersey and Pennsylvania courts.
- Novo Nordisk disputes the lawsuits and cites company-funded studies that found no increased risk of NAION from their drugs.
- Scientists have researched the possible link for years, with mixed findings; some studies show a small risk, others do not.
- NAION typically occurs within 6 to 18 months of starting a GLP-1 medication.
- The US Food and Drug Administration (FDA) is investigating the potential risk but has not yet required warnings on the drugs.
- The European Medicines Agency estimates NAION might affect 1 in 10,000 GLP-1 users with diabetes.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
